Brooklyn, NY, USA, June 18, 2024 /EINPresswire.com/ — The plaque psoriasis market is poised for substantial growth, projected to achieve a CAGR of 8.93% from 2024 to 2034 across key regions including the United States, EU5 (Germany, Spain, Italy, France, United Kingdom), and Japan. A recent market report provides an in-depth analysis covering treatment methodologies, current and emerging pharmaceuticals, market share of therapies, and the performance of major companies within the sector. This comprehensive study is crucial for stakeholders such as manufacturers, investors, and healthcare professionals involved in the plaque psoriasis market.
One of the primary drivers of market growth is the advent of biological therapies, which have revolutionized the treatment landscape for plaque psoriasis. These therapies have significantly expanded treatment options, contributing to the market’s robust expansion. Concurrently, advancements in dermatological imaging techniques have enhanced diagnostic accuracy, further supporting market growth.
The integration of telehealth services has also played a pivotal role by improving patient access to timely care and treatment options. This shift towards patient-centered care is reflective of a broader trend where individuals affected by plaque psoriasis increasingly seek effective treatments that alleviate symptoms and enhance quality of life.
Recognizing the substantial burden of plaque psoriasis on both patients and healthcare systems, governments and healthcare agencies have initiated policy measures and funding support to advance research and improve patient access to care. International collaborations in research and clinical trials are further expected to accelerate market growth by promoting awareness and facilitating the development of innovative therapies.
The report covers detailed analyses of historical, current, and projected epidemiology scenarios, market performance across therapeutic categories, sales dynamics of drugs, reimbursement scenarios, and insights into both in-market and late-stage pipeline drugs for plaque psoriasis treatment.
Competitive Landscape
The competitive landscape includes detailed profiles of key players in the plaque psoriasis market, such as Ortho Dermatologics, AstraZeneca/Bausch Health Companies/Kyowa Kirin/LEO Pharma, Almirall/Sun Pharmaceutical Industries, Arcutis Biotherapeutics, and Pfizer.
For further insights and customization options, please visit IMARC Group.
About IMARC Group
IMARC Group is a leading market research company offering management strategies and market research globally. The company collaborates with clients across sectors to identify opportunities, address challenges, and drive transformative growth. IMARC’s expertise spans major markets, scientific advancements, economic trends, and technological developments, catering to pharmaceuticals, industrial sectors, and high technology organizations.
This release summarizes the latest findings on the plaque psoriasis market, emphasizing growth drivers, key innovations, and strategic insights essential for stakeholders navigating this dynamic sector.
Related Topics:
